Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics

Björn Pasternak, Per Aspenberg, Björn Pasternak, Per Aspenberg

Abstract

Matrix metalloproteinases (MMPs) and related enzymes (ADAMs, ADAMTS) and their inhibitors control matrix turnover and function. Recent advances in our understanding of musculoskeletal conditions such as tendinopathy, arthritis, Dupuytren's disease, degenerative disc disease, and bone and soft tissue healing suggest that MMPs have prominant roles. Importantly, MMPs are amenable to inhibition by cheap, safe, and widely available drugs such as the tetracycline antibiotics and the bisphosphonates. This indicates that these MMP inhibitors, if proven effective for any novel indication, may be quickly brought into clinical practice.

Figures

Figure 1.
Figure 1.
Degradation of the extracellular matrix is principally mediated by MMPs, which are counterbalanced by TIMPs. Disturbances of this equilibrium may lead to disease processes of fibrotic nature (left) or degradative nature (right).
Figure 2.
Figure 2.
Simplified drawing of MMP regulation. MMP gene transcription is generally induced by stimuli such as inflammatory cytokines, which signal via specific intracellular pathways. MMPs are produced as inactive pro-enzymes that are subsequently cleaved to become active enzymes. MMP-3 appears particularly important in this regard, since it is known to activate several of the MMPs. Plasmin is also an important activator of MMPs. TIMPs inhibit MMPs mainly at the active level. MAPK: mitogen-activated protein kinase.
Figure 3.
Figure 3.
Mechanisms of action of tetracyclines. Tetracyclines have several non-antimicrobial effects. The ability of these drugs to inhibit matrix metalloproteinases is well established. Based on this mechanism, tetracyclines have shown clinical effects on rheumatoid arthritis and periodontitis. Doxycycline and minocycline are the two tetracyclines that have been studied most extensively. TNF: tumor necrosis factor; IL: interleukin; NO: nitric oxide; PG: prostaglandin.

References

    1. Ackermann PW, Li J, Lundeberg T, Kreicbergs A. Neuronal plasticity in relation to nociception and healing of rat achilles tendon. J Orthop Res. 2003;21((3)):432–41.
    1. Agren MS, Jorgensen LN, Andersen M, Viljanto J, Gottrup F. Matrix metalloproteinase 9 level predicts optimal collagen deposition during early wound repair in humans. Br J Surg. 1998;85((1)):68–71.
    1. Ala-Kokko L. Genetic risk factors for lumbar disc disease. Ann Med. 2002;34((1)):42–7.
    1. Alfredson H. The chronic painful Achilles and patellar tendon: research on basic biology and treatment. Scand J Med Sci Sports. 2005;15((4)):252–9.
    1. Alfredson H, Lorentzon M, Backman S, Backman A, Lerner UH. cDNA-arrays and real-time quantitative PCR techniques in the investigation of chronic Achilles tendinosis. J Orthop Res. 2003;21((6)):970–5.
    1. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A. 1996;93((24)):14014–9.
    1. Arnoczky SP, Lavagnino M, Egerbacher M, Caballero O, Gardner K. Matrix metalloproteinase inhibitors prevent a decrease in the mechanical properties of stress-deprived tendons: an in vitro experimental study. Am J Sports Med. 2007;35((5)):763–9.
    1. Aulisa L, Papaleo P, Pola E, Angelini F, Aulisa AG, Tamburrelli FC, Pola P, Logroscino CA. Association between IL-6 and MMP-3 gene polymorphisms and adolescent idiopathic scoliosis: a case-control study. Spine. 2007;32((24)):2700–2.
    1. Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren's contracture. J Hand Surg (Am) 2007;32((6)):767–74.
    1. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002;115((Pt 19)):3719–27.
    1. Behera AK, Hildebrand E, Szafranski J, Hung HH, Grodzinsky A, Lafyatis R, Koch AE, Kalish R, Perides G, Steere AC, Hu LT. Role of aggrecanase 1 in Lyme arthritis. Arthritis Rheum. 2006;54((10)):3319–29.
    1. Bramono DS, Richmond JC, Weitzel PP, Kaplan DL, Altman GH. Matrix metalloproteinases and their clinical applications in orthopaedics. Clin Orthop. 2004;((428)):272–85.
    1. Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, Wolfe F, Schnitzer TJ, Moreland LW, Manzi S, Bradley JD, Sharma L, Oddis CV, Hugenberg ST, Heck LW. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum. 2005;52((7)):2015–25.
    1. Brown R, Orchard J, Kinchington M, Hooper A, Nalder G. Aprotinin in the management of Achilles tendinopathy: a randomised controlled trial. Br J Sports Med. 2006;40((3)):275–9.
    1. Bunker TD, Reilly J, Baird KS, Hamblen DL. Expression of growth factors, cytokines and matrix metalloproteinases in frozen shoulder. J Bone Joint Surg (Br) 2000;82((5)):768–73.
    1. Burssens P, Steyaert A, Forsyth R, van Ovost EJ, Depaepe Y, Verdonk R. Exogenously administered substance P and neutral endopeptidase inhibitors stimulate fibroblast proliferation, angiogenesis and collagen organization during Achilles tendon healing. Foot Ankle Int. 2005;26((10)):832–9.
    1. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003;253((1-2)):269–85.
    1. Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, Liang TH, Liao TH, Tsai CY, Wei JC, Chou CT. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 2006;45((4)):414–20.
    1. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006;25((1)):99–113.
    1. Constantin A, Lauwers-Cances V, Navaux F, Abbal M, van Meerwijk J, Mazieres B, Cambon-Thomsen A, Cantagrel A. Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: Association with severity and progression of rheumatoid arthritis in a prospective study. Arthritis Rheum. 2002;46((7)):1754–62.
    1. Corps AN, Curry VA, Buttle DJ, Hazleman BL, Riley GP. Inhibition of interleukin-1beta-stimulated collagenase and stromelysin expression in human tendon fibroblasts by epigallocatechin gallate ester. Matrix Biol. 2004;23((3)):163–9.
    1. Corps AN, Robinson AH, Movin T, Costa ML, Hazleman BL, Riley GP. Increased expression of aggrecan and biglycan mRNA in Achilles tendinopathy. Rheumatology. 2006;45((3)):291–4.
    1. Corps AN, Jones GC, Harrall RL, Curry VA, Hazleman BL, Riley GP. The regulation of aggrecanase ADAMTS-4 expression in human Achilles tendon and tendon-derived cells. Matrix Biol. 2008;27((5)):393–401.
    1. Cury PR, Canavez F, de Araujo VC, Furuse C, de Araujo NS. Substance P regulates the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in cultured human gingival fibroblasts. J Periodontal Res. 2008;43((3)):255–60.
    1. Davidson RK, Waters JG, Kevorkian L, Darrah C, Cooper A, Donell ST, Clark IM. Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage. Arthritis Res Ther. 2006;8((4)):R124.
    1. de Mos M, van El B, DeGroot J, Jahr H, van Schie HT, van Arkel ER, Tol H, Heijboer R, van Osch GJ, Verhaar JA. Achilles tendinosis: changes in biochemical composition and collagen turnover rate. Am J Sports Med. 2007;35((9)):1549–56.
    1. de Mos M, Joosten LA, Oppers-Walgreen B, van Schie JT, Jahr H, van Osch GJ, Verhaar JA. Tendon degeneration is not mediated by regulation of Toll-like receptors 2 and 4 in human tenocytes. J Orthop Res. 2009;27((8)):1043–7.
    1. Demirag B, Sarisozen B, Ozer O, Kaplan T, Ozturk C. Enhancement of tendon-bone healing of anterior cruciate ligament grafts by blockage of matrix metalloproteinases. J Bone Joint Surg (Am) 2005;87((11)):2401–10.
    1. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res. 2006;69((3)):625–35.
    1. Dong DM, Yao M, Liu B, Sun CY, Jiang YQ, Wang YS. Association between the -1306C/T polymorphism of matrix metalloproteinase-2 gene and lumbar disc disease in Chinese young adults. Eur Spine J. 2007;16((11)):1958–61.
    1. Eliasson P, Fahlgren A, Aspenberg P. Mechanical load and BMP signaling during tendon repair: a role for follistatin? Clin Orthop. 2008;((466)):1592–7.
    1. Emingil G, Atilla G, Sorsa T, Luoto H, Kirilmaz L, Baylas H. The effect of adjunctive low-dose doxycycline therapy on clinical parameters and gingival crevicular fluid matrix metalloproteinase-8 levels in chronic periodontitis. J Periodontol. 2004;75((1)):106–15.
    1. Fiedorczyk M, Klimiuk PA, Sierakowski S, Gindzienska-Sieskiewicz E, Chwiecko J. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. J Rheumatol. 2006;33((8)):1523–9.
    1. Foos MJ, Hickox JR, Mansour PG, Slauterbeck JR, Hardy DM. Expression of matrix metalloprotease and tissue inhibitor of metalloprotease genes in human anterior cruciate ligament. J Orthop Res. 2001;19((4)):642–9.
    1. Franceschi F, Longo UG, Ruzzini L, Morini S, Battistoni F, Dicuonzo G, Maffulli N, Denaro V. Circulating substance P levels and shoulder joint contracture after arthroscopic repair of the rotator cuff. Br J Sports Med. 2008;42((9)):742–5.
    1. Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie. 2005;87((3-4)):361–8.
    1. Gjertsson I, Innocenti M, Matrisian LM, Tarkowski A. Metalloproteinase-7 contributes to joint destruction in Staphylococcus aureus induced arthritis. Microb Pathog. 2005;38((2-3)):97–105.
    1. Godoy-Santos AL, D'Elia CO, Teixeira WJ, Cabrita HB, Camanho GL. Aseptic loosening of total hip arthroplasty: Preliminary genetic investigation. J Arthroplasty. 2009;24((2)):297–302.
    1. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12((2)):12–26.
    1. Goupille P, Jayson MI, Valat JP, Freemont AJ. Matrix metalloproteinases: the clue to intervertebral disc degeneration? Spine. 1998;23((14)):1612–26.
    1. Green MJ, Gough AK, Devlin J, Smith J, Astin P, Taylor D, Emery P. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2003;42((1)):83–8.
    1. Gueders MM, Balbin M, Rocks N, Foidart JM, Gosset P, Louis R, Shapiro S, Lopez-Otin C, Noël A, Cataldo DD. Matrix metalloproteinase-8 deficiency promotes granulocytic allergen-induced airway inflammation. J Immunol. 2005;175((4)):2589–97.
    1. Heikkila P, Teronen O, Moilanen M, Konttinen YT, Hanemaaijer R, Laitinen M, Maisi P, van der Pluijm G, Bartlett JD, Salo T, Sorsa T. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs. 2002;13((3)):245–54.
    1. Henle P, Zimmermann G, Weiss S. Matrix metalloproteinases and failed fracture healing. Bone. 2005;37((6)):791–8.
    1. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93((3)):178–93.
    1. Hu LT, Eskildsen MA, Masgala C, Steere AC, Arner EC, Pratta MA, Grodzinsky AJ, Loening A, Perides G. Host metalloproteinases in Lyme arthritis. Arthritis Rheum. 2001;44((6)):1401–10.
    1. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007;6((6)):480–98.
    1. Hutchinson JW, Tierney GM, Parsons SL, Davis TR. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg (Br) 1998;80((5)):907–8.
    1. Illman SA, Lehti K, Keski-Oja J, Lohi J. Epilysin (MMP-28) induces TGF-beta mediated epithelial to mesenchymal transition in lung carcinoma cells. J Cell Sci. 2006;119((Pt 18)):3856–65.
    1. Johnston P, Chojnowski AJ, Davidson RK, Riley GP, Donell ST, Clark IM. A complete expression profile of matrix-degrading metalloproteinases in Dupuytren's disease. J Hand Surg (Am) 2007;32((3)):343–51.
    1. Johnston P, Larson D, Clark IM, Chojnowski AJ. Metalloproteinase gene expression correlates with clinical outcome in Dupuytren's disease. J Hand Surg (Am) 2008;33((7)):1160–7.
    1. Jones GC, Riley GP. ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis. Arthritis Res Ther. 2005;7((4)):160–9.
    1. Jones GC, Corps AN, Pennington CJ, Clark IM, Edwards DR, Bradley MM, Hazleman BL, Riley GP. Expression profiling of metalloproteinases and tissue inhibitors of metalloproteinases in normal and degenerate human achilles tendon. Arthritis Rheum. 2006;54((3)):832–42.
    1. Kanangat S, Postlethwaite A, Hasty K, Kang A, Smeltzer M, Appling W, Schaberg G. Induction of multiple matrix metalloproteinases in human dermal and synovial fibroblasts by Staphylococcus aureus: implications in the pathogenesis of septic arthritis and other soft tissue infections. Arthritis Res Ther. 2006;8((6)):R176.
    1. Karousou E, Ronga M, Vigetti D, Passi A, Maffulli N. Collagens, proteoglycans, MMP-2, MMP-9 and TIMPs in human achilles tendon rupture. Clin Orthop. 2008;((466)):1577–82.
    1. Kloppenburg M, Brinkman BM, de Rooij-Dijk HH, Miltenburg AM, Daha MR, Breedveld FC, Dijkmans BA, Verweij C. The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrob Agents Chemother. 1996;40((4)):934–40.
    1. Kossakowska AE, Edwards DR, Prusinkiewicz C, Zhang MC, Guo D, Urbanski SJ, Grogan T, Marquez LA, Janowska-Wieczorek A. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood. 1999;94((6)):2080–9.
    1. Krzeski P, Buckland-Wright C, Balint G, Cline GA, Stoner K, Lyon R, Beary J, Aronstein WS, Spector TD. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther. 2007;9((5)):R109.
    1. Kuula H, Salo T, Pirila E, Tuomainen AM, Jauhiainen M, Uitto VJ, Tjaderhane L, Pussinen PJ, Sorsa T. Local and systemic responses in matrix metalloproteinase 8-deficient mice during Porphymonas gingivalis-induced periodontitis. Infect Immun. 2009;77((2)):850–9.
    1. Lauhio A, Leirisalo-Repo M, Lahdevirta J, Saikku P, Repo H. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum. 1991;34((1)):6–14.
    1. Lee CZ, Xu B, Hashimoto T, McCulloch CE, Yang GY, Young WL. Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke. 2004;35((7)):1715–9.
    1. Li TF, Santavirta S, Virtanen I, Kononen M, Takagi M, Konttinen YT. Increased expression of EMMPRIN in the tissue around loosened hip prostheses. Acta Orthop Scand. 1999;70((5)):446–51.
    1. Liu X, Han Q, Sun R, Li Z. Dexamethasone regulation of matrix metalloproteinase expression in experimental pneumococcal meningitis. Brain Res. 2008;1207:237–43.
    1. Lo IK, Marchuk LL, Hollinshead R, Hart DA, Frank CB. Matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase mRNA levels are specifically altered in torn rotator cuff tendons. Am J Sports Med. 2004;32((5)):1223–9.
    1. Lohmander LS, Brandt KD, Mazzuca SA, Katz BP, Larsson S, Struglics A, Lane KA. Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritis. Arthritis Rheum. 2005;52((10)):3160–7.
    1. Magra M, Maffulli N. Matrix metalloproteases: a role in overuse tendinopathies. Br J Sports Med. 2005;39((11)):789–91.
    1. Maksymowych WP, Landewe R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, Poole AR, Wang N, van der Heijde D. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum. 2007;56((6)):1846–53.
    1. Maksymowych WP, Rahman P, Shojania K, Olszynski WP, Thomson GT, Ballal S, Wong RL, Inman RD. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol. 2008;35((10)):2030–7.
    1. Malik MH, Jury F, Bayat A, Ollier WE, Kay PR. Genetic susceptibility to total hip arthroplasty failure: a preliminary study on the influence of matrix metalloproteinase 1, interleukin 6 polymorphisms and vitamin D receptor. Ann Rheum Dis. 2007;66((8)):1116–20.
    1. Mandal M, Mandal A, Das S, Chakraborti T, Sajal C. Clinical implications of matrix metalloproteinases. Mol Cell Biochem. 2003;252((1-2)):305–29.
    1. Mannello F. Serum or plasma samples? The “Cinderella” role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation. Arterioscler Thromb Vasc Biol. 2008;28((4)):611–4.
    1. Martignetti JA, Aqeel AA, Sewairi WA, Boumah CE, Kambouris M, Mayouf SA, Sheth KV, Eid WA, Dowling O, Harris J, Glucksman MJ, Bahabri S, Meyer BF, Desnick RJ. Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nat Genet. 2001;28((3)):261–5.
    1. Mattey DL, Nixon NB, Dawes PT, Ollier WE, Hajeer AH. Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arthritis. Genes Immun. 2004;5((2)):147–9.
    1. McDowell CL, Marqueen TJ, Yager D, Owen J, Wayne JS. Characterization of the tensile properties and histologic/biochemical changes in normal chicken tendon at the site of suture insertion. J Hand Surg (Am) 2002;27((4)):605–14.
    1. Meller D, Li DQ, Tseng SC. Regulation of collagenase, stromelysin, and gelatinase B in human conjunctival and conjunctivochalasis fibroblasts by interleukin-1beta and tumor necrosis factor-alpha. Invest Ophthalmol Vis Sci. 2000;41((10)):2922–9.
    1. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007;98((5)):621–8.
    1. Mokone GG, Schwellnus MP, Noakes TD, Collins M. The COL5A1 gene and Achilles tendon pathology. Scand J Med Sci Sports. 2006;16((1)):19–26.
    1. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69((3)):562–73.
    1. Nakashima Y, Sun DH, Maloney WJ, Goodman SB, Schurman DJ, Smith RL. Induction of matrix metalloproteinase expression in human macrophages by orthopaedic particulate debris in vitro. J Bone Joint Surg (Br) 1998;80((4)):694–700.
    1. O'Dell JR, Blakely KW, Mallek JA, Eckhoff PJ, Leff RD, Wees SJ, Sems KM, Fernandez AM, Palmer WR, Klassen LW, Paulsen GA, Haire CE, Moore GF. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum. 2001;44((10)):2235–41.
    1. O'Dell JR, Elliott JR, Mallek JA, Mikuls TR, Weaver CA, Glickstein S, Blakley KM, Hausch R, Leff RD. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. Arthritis Rheum. 2006;54((2)):621–7.
    1. Odio CM, Ramirez T, Arias G, Abdelnour A, Hidalgo I, Herrera ML, Bolanos W, Alpizar J, Alvarez P. Double blind, randomized, placebo-controlled study of dexamethasone therapy for hematogenous septic arthritis in children. Pediatr Infect Dis J. 2003;22((10)):883–8.
    1. Ong SM, Taylor GJ. Doxycycline inhibits bone resorption by human interface membrane cells from aseptically loose hip replacements. J Bone Joint Surg (Br) 2003;85((3)):456–61.
    1. Orchard J, Massey A, Brown R, Cardon-Dunbar A, Hofmann J. Successful management of tendinopathy with injections of the MMP-inhibitor aprotinin. Clin Orthop. 2008;((466)):1625–32.
    1. Oshiro W, Lou J, Xing X, Tu Y, Manske PR. Flexor tendon healing in the rat: a histologic and gene expression study. J Hand Surg (Am) 2003;28((5)):814–23.
    1. Owen CA, Hu Z, Lopez-Otin C, Shapiro SD. Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase. J Immunol. 2004;172((12)):7791–803.
    1. Pasternak B, Fellenius M, Aspenberg P. Doxycycline impairs tendon repair in rats. Acta Orthop Belg. 2006;72((6)):756–60.
    1. Pasternak B, Missios A, Askendal A, Tengvall P, Aspenberg P. Doxycycline-coated sutures improve the suture-holding capacity of the rat Achilles tendon. Acta Orthop. 2007;78((5)):680–6.
    1. Pasternak B, Rehn M, Andersen L, Agren MS, Heegaard AM, Tengvall P, Aspenberg P. Doxycycline-coated sutures improve mechanical strength of intestinal anastomoses. Int J Colorectal Dis. 2008a;23((3)):271–6.
    1. Pasternak B, Schepull T, Eliasson P, Aspenberg P. Elevation of systemic matrix metalloproteinase-2 and -7 and tissue inhibitor of metalloproteinases-2 in patients with a history of Achilles tendon rupture: pilot study. Br J Sports Med. 2008b Epub ahead of print.
    1. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev. 2003;22((2-3)):177–203.
    1. Pearce WH, Shively VP. Abdominal aortic aneurysm as a complex multifactorial disease: interactions of polymorphisms of inflammatory genes, features of autoimmunity, and current status of MMPs. Ann N Y Acad Sci. 2006;1085:117–32.
    1. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev. 2004;9((1)):63–79.
    1. Pockert AJ, Richardson SM, Le Maitre CL, Lyon M, Deakin JA, Buttle DJ, Freemont AJ, Hoyland JA. Modified expression of the ADAMTS enzymes and tissue inhibitor of metalloproteinases 3 during human intervertebral disc degeneration. Arthritis Rheum. 2009;60((2)):482–91.
    1. Raleigh SM, Van der Merwe L, Ribbans WJ, Smith RK, Schwellnus MP, Collins M. Variants within the MMP3 gene are associated with Achilles tendinopathy: Possible interaction with the COL5A1 gene. Br J Sports Med. 2009;43((7)):514–20.
    1. Rees JD, Wilson AM, Wolman RL. Current concepts in the management of tendon disorders. Rheumatology (Oxford) 2006;45((5)):508–21.
    1. Ren XH, Peng XD, Wu XP, Liao EY, Sun ZQ. Association between serum soluble membrane type matrix metalloproteinase-1 (MT1-MMP) levels and bone mineral density, and biochemical markers in postmenopausal women. Clin Chim Acta. 2008;390((1-2)):44–8.
    1. Rengel Y, Ospelt C, Gay S. Proteinases in the joint: clinical relevance of proteinases in joint destruction. Arthritis Res Ther. 2007;9((5)):221.
    1. Riley G. The pathogenesis of tendinopathy. A molecular perspective. Rheumatology. 2004;43((2)):131–42.
    1. Riley G. Tendinopathy--from basic science to treatment. Nat Clin Pract Rheumatol. 2008;4((2)):82–9.
    1. Riley GP, Curry V, DeGroot J, van El B, Verzijl N, Hazleman BL, Bank RA. Matrix metalloproteinase activities and their relationship with collagen remodelling in tendon pathology. Matrix Biol. 2002;21((2)):185–95.
    1. Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, Brinckerhoff CE. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 1998;58((23)):5321–5.
    1. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59((6)):762–84.
    1. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54((2)):258–65.
    1. Schubert TE, Weidler C, Lerch K, Hofstadter F, Straub RH. Achilles tendinosis is associated with sprouting of substance P positive nerve fibres. Ann Rheum Dis. 2005;64((7)):1083–6.
    1. Smieja M, MacPherson DW, Kean W, Schmuck ML, Goldsmith CH, Buchanan W, Hart LE, Mahony JB. Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis. Ann Rheum Dis. 2001;60((12)):1088–94.
    1. Steyaert AE, Burssens PJ, Vercruysse CW, Vanderstraeten GG, Verbeeck RM. The effects of substance P on the biomechanic properties of ruptured rat Achilles' tendon. Arch Phys Med Rehabil. 2006;87((2)):254–8.
    1. Stumpf M, Klinge U, Wilms A, Zabrocki R, Rosch R, Junge K, Krones C, Schumpelick V. Changes of the extracellular matrix as a risk factor for anastomotic leakage after large bowel surgery. Surgery. 2005;137((2)):229–34.
    1. Sundfeldt M, Carlsson LV, Johansson CB, Thomsen P, Gretzer C. Aseptic loosening, not only a question of wear: a review of different theories. Acta Orthop. 2006;77((2)):177–97.
    1. Syk I, Agren MS, Adawi D, Jeppsson B. Inhibition of matrix metalloproteinases enhances breaking strength of colonic anastomoses in an experimental model. Br J Surg. 2001;88((2)):228–34.
    1. Takagi M. Neutral proteinases and their inhibitors in the loosening of total hip prostheses. Acta Orthop Scand (Suppl 271) 1996:3–29.
    1. Takahashi M, Haro H, Wakabayashi Y, Kawa-uchi T, Komori H, Shinomiya K. The association of degeneration of the intervertebral disc with 5a/6a polymorphism in the promoter of the human matrix metalloproteinase-3 gene. J Bone Joint Surg (Br) 2001;83((4)):491–5.
    1. Takaishi H, Kimura T, Dalal S, Okada Y, D'Armiento J. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr Pharm Biotechnol. 2008;9((1)):47–54.
    1. Tallon C, Maffulli N, Ewen SW. Ruptured Achilles tendons are significantly more degenerated than tendinopathic tendons. Med Sci Sports Exerc. 2001;33((12)):1983–90.
    1. Tamargo RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Res. 1991;51((2)):672–5.
    1. Tchetverikov I, Ronday HK, Van El B, Kiers GH, Verzijl N, TeKoppele JM, Huizinga TW, DeGroot J, Hanemaaijer R. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63((7)):881–3.
    1. Tchetverikov I, Kraan MC, van El B, Hanemaaijer R, DeGroot J, Huizinga TW. Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with alpha2 macroglobulin in serum of rheumatoid arthritis patients. Ann Rheum Dis. 2008;67((1)):128–30.
    1. Townley WA, Cambrey AD, Khaw PT, Grobbelaar AO. Matrix metalloproteinase inhibition reduces contraction by dupuytren fibroblasts. J Hand Surg (Am) 2008;33((9)):1608–16.
    1. Tsukahara S, Shinozaki M, Ikari K, Mochizuki T, Inoue E, Tomatsu T, Hara M, Yamanaka H, Kamatani N, Momohara S. Effect of matrix metalloproteinase-3 functional SNP on serum matrix metalloproteinase-3 level and outcome measures in Japanese RA patients. Rheumatology (Oxford) 2008;47((1)):41–4.
    1. Ulrich D, Hrynyschyn K, Pallua N. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease. Plast Reconstr Surg. 2003;112((5)):1279–86.
    1. Wada A, Kubota H, Miyanishi K, Hatanaka H, Miura H, Iwamoto Y. Comparison of postoperative early active mobilization and immobilization in vivo utilising a four-strand flexor tendon repair. J Hand Surg (Br) 2001;26((4)):301–6.
    1. Walker C, Preshaw PM, Novak J, Hefti AF, Bradshaw M, Powala C. Long-term treatment with sub-antimicrobial dose doxycycline has no antibacterial effect on intestinal flora. J Clin Periodontol. 2005;32((11)):1163–9.
    1. van der Laan W, Molenaar E, Ronday K, Verheijen J, Breedveld F, Greenwald R, Dijkmans B, TeKoppele J. Lack of effect of doxycycline on disease activity and joint damage in patients with rheumatoid arthritis. A double blind, placebo controlled trial. J Rheumatol. 2001;28((9)):1967–74.
    1. van Meurs J, van Lent P, Stoop R, Holthuysen A, Singer I, Bayne E, Mudgett J, Poole R, Billinghurst C, van der Kraan P, Buma P, van den Berg W. Cleavage of aggrecan at the Asn341-Phe342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity. Arthritis Rheum. 1999;42((10)):2074–84.
    1. Watelet JB, Claeys C, Van Cauwenberge P, Bachert C. Predictive and monitoring value of matrix metalloproteinase-9 for healing quality after sinus surgery. Wound Repair Regen. 2004;12((4)):412–8.
    1. Weitoft T, Larsson A, Ronnblom L. Serum levels of sex steroid hormones and matrix metalloproteinases after intra-articular glucocorticoid treatment in female patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67((3)):422–4.
    1. Verdrengh M, Carlsten H, Ohlsson C, Tarkowski A. Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis. J Orthop Res. 2007;25((3)):304–10.
    1. Virchenko O, Aspenberg P. How can one platelet injection after tendon injury lead to a stronger tendon after 4 weeks? Interplay between early regeneration and mechanical stimulation. Acta Orthop. 2006;77((5)):806–12.
    1. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92((8)):827–39.
    1. Witte MB, Thornton FJ, Kiyama T, Efron DT, Schulz GS, Moldawer LL, Barbul A. Metalloproteinase inhibitors and wound healing: a novel enhancer of wound strength. Surgery. 1998;124((2)):464–70.
    1. Voloshin I, Gelinas J, Maloney MD, O'Keefe RJ, Bigliani LU, Blaine TA. Proinflammatory cytokines and metalloproteases are expressed in the subacromial bursa in patients with rotator cuff disease. Arthroscopy. 2005;21((9)):1076.
    1. Yildirim Y, Kara H, Cabukoglu C, Esemenli T. Suture holding capacity of the Achilles tendon during the healing period: an in vivo experimental study in rabbits. Foot Ankle Int. 2006;27((2)):121–4.
    1. Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, Saxne T, Robins S, Griffiths I. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum. 2007;56((10)):3236–47.
    1. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A. 1999;96((23)):13496–500.
    1. Zimmermann G, Henle P, Kusswetter M, Moghaddam A, Wentzensen A, Richter W, Weiss S. TGF-beta1 as a marker of delayed fracture healing. Bone. 2005;36((5)):779–85.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe